The NECTAR-HF ( NEural Cardiac TherApy foR Heart Failure ) trial is designed to evaluate whether the Boston Scientific VNS device is safe and may attenuate cardiac remodelling , improve cardiac function and increase exercise capacity , in symptomatic heart failure patients ( New York Heart Association Class II-III ) with left ventricular systolic dysfunction ( ejection fraction 35 % ) and receiving optimal medical therapy .